Scancell Soars On 'Universal' COVID-19 Vaccine Claims
Phase I Trial Imminent
Executive Summary
The current coronavirus vaccines focus on the spike protein but the UK's Scancell believes it has a candidate that also targets the SARS-CoV-2 nucleocapsid protein which could help tackle existing and future variants.